Container closure integrity (CCI) is one of the requirements for a sterile packaging system.
For vial-based systems, the capping process is a critical step in creating and ensuring an …

Capping completes the closure of parenteral drug products in the final packaging container
and is critical in maintaining an integral seal to ensure product quality. Residual seal force …

Parenteral drug products are protected by appropriate primary packaging to protect against
environmental factors, including potential microbial contamination during shelf life duration …

The majority of parenteral drug products are manufactured in glass vials with an elastomeric
rubber stopper and a crimp cap. The vial sealing process is a critical process step during fill …

The vial capping process is a critical unit operation during drug product manufacturing, as it
could possibly generate cosmetic defects or even affect container closure integrity. Yet there …

A new major chapter dealing with container closure integrity was released by the United
States Pharmacopeial Convention. Chapter< 1207> provides a significant amount of …

Sterile pharmaceuticals require they be developed and manufactured using suitable
container closure systems to maintain sterility until product opening. Characterizing …

Capping equipment used in good manufacturing practice manufacturing features different
designs and a variety of adjustable process parameters. The overall capping result is a …

Capping equipment used in good manufacturing practice (GMP) manufacturing feature
different designs and a variety of adjustable process parameters. The overall capping result …

Compatible vial container closure system (CCS) components in combination with a proper
capping process are crucial to ensuring reliable performance, maintaining container closure …